Lion Point Capital, LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Lion Point Capital, LP disclosed 21 US equity positions worth $15.7m in its Q1 2025 13F filing. The largest position was INSM at 14.8% of the reported book, followed by ARDX and MLYS. Against the Q4 2024 filing, it opened 2 new positions, added to 2 and reduced 3 among the top 21 holdings.
What did Lion Point Capital, LP own in Q1 2025? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | INSM INSMED INC | Healthcare | 14.8% | $2.3m | 30,500 | -17% | reduced |
| 2 | ARDX ARDELYX INC | Healthcare | 10.5% | $1.6m | 335,400 | 0% | held |
| 3 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 8.0% | $1.3m | 79,000 | 0% | held |
| 4 | FENC FENNEC PHARMACEUTICALS INC | 7.6% | $1.2m | 195,700 | 0% | held | |
| 5 | KINIKSA PHARMACEUTICALS LTD | 6.5% | $1.0m | 45,900 | 0% | held | |
| 6 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 5.7% | $898.8k | 26,000 | -35% | reduced |
| 7 | BENITEC BIOPHARMA INC | 5.1% | $806.6k | 62,000 | 0% | held | |
| 8 | GERN GERON CORP | Healthcare | 5.1% | $795.0k | 500,000 | 0% | held |
| 9 | AVADEL PHARMACEUTICALS PLC | 4.9% | $772.8k | 98,700 | 54% | added | |
| 10 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 4.6% | $724.1k | 46,300 | 0% | held |
| 11 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 4.3% | $675.7k | 55,000 | 0% | held |
| 12 | JSPR JASPER THERAPEUTICS INC | 4.0% | $630.0k | 146,500 | 358% | added | |
| 13 | BHVN BIOHAVEN LTD | Healthcare | 3.5% | $545.7k | 22,700 | 0% | held |
| 14 | IRON DISC MEDICINE INC | Healthcare | 3.4% | $526.2k | 10,600 | 0% | held |
| 15 | MIST MILESTONE PHARMACEUTICALS IN | 2.8% | $439.1k | 548,806 | -47% | reduced | |
| 16 | RGNX REGENXBIO INC | Healthcare | 2.6% | $412.9k | 57,750 | 0% | held |
| 17 | BLUEBIRD BIO INC | 2.5% | $385.1k | 78,912 | 0% | held | |
| 18 | MCRB SERES THERAPEUTICS INC | Healthcare | 1.5% | $238.5k | 340,761 | 0% | held |
| 19 | MERSANA THERAPEUTICS INC | 1.4% | $221.7k | 644,000 | – | new | |
| 20 | HUMA HUMACYTE INC | 0.9% | $142.4k | 83,500 | – | new | |
| 21 | SPRB SPRUCE BIOSCIENCES INC | 0.1% | $21.8k | 75,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.